Exam 1 - Random Info Flashcards
6-MP polymorphism
TPMT loss of function
cytarabine synergy agent
a. leucovorin
b. tetrahydrouridine
c. dexrazoxane
d. 5-FU
b. tetrahydrouridine
cisplatin toxicity
nephrotoxicity
irinotecan polymorphism
a. TPMT
b. UGT1A1
c. BRAF-V600
d. T315l
b. UGT1A1
drug given with doxorubicin to protect against anthracycline-induced cardiotoxicity
dexrazoxane
bleomycin main toxicity
pulmonary
which has a lower rate of neurotoxicity?
a. vincristine
b. eribulin
b. eribulin
formulation for GnRH analogs for breast cancer (i.e. leuprolide)
depot
which drug does not result in “flare” of testosterone production?
a. leuprolide
b. goserelin
c. triptorelin
d. degarelix
d. degarelix
common SE of abiraterone
inc cholesterol levels
what drug inhibits the function of 17 alpha-hydroxylase and C17,20 lyase?
a. abiraterone
b. fulvestrant
c. exemestane
d. alectinib
a. abiraterone
drug that can inhibit the “gatekeeper” T315l mutation
a. alectinib
b. quizartinib
c. ponatinib
d. dabrafenib
c. ponatinib
drug that is specific for internal tandem duplication (ITD) mutations
a. sirolimus
b. alectinib
c. quizartinib
d. trametinib
c. quizartinib
which drug inhibits immune response by blocking IL-2 signaling transduction?
a. sirolimus
b. dabrafenib
c. trametinib
d. afatinib
a. sirolimus
which drug is a type III allosteric kinase inhibitor?
a. gefitinib
b. alectinib
c. trametinib
d. acalabrutinib
c. trametinib
what drug is used in combo with trametinib for BRAFV600E mutant metastatic melanoma?
dabrafenib
kinase inhibitor that is effective for T790M mutation
a. trametinib
b. lapatinib
c. tucatinib
d. osimertinib
d. osimertinib
drug that is EGFR and HER2 reversible inhibitor
lapatinib
which antibody is it mentioned that there is ~3% severe infusion reaction?
cetuximab
antibody that targets VEGF
bevacizumab
antibody that targets VEGF receptor
a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab
b. ramucirumab
antibody that binds CD20 only to inhibit B-cell proliferation
a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab
d. rituximab
antibody that targets CD38, a protein highly expressed on plasma B cells that make antibodies
a. ipilimumbab
b. ramucirumab
c. daratumumab
d. rituximab
c. daratumumab
antibody that targets CTLA-4 receptor and has a severe inflammatory response
a. ipilimumab
b. ramucirumab
c. daratumumab
d. rituximab
a. ipilimumab
antibody that binds PD-1 receptor expressed on T-cells
a. atezolizumab
b. pembrolizumab
c. trastuzumab emtansine
d. teclistamab
b. pembrolizumab
antibody that binds PD-L1 receptor expressed on macrophages and tumor cells
a. atezolizumab
b. pembrolizumab
c. trastuzumab emtansine
d. teclistamab
a. atezolizumab
mouse, chimeric, humanized, and fully human
mouse = o
chimeric = xi
humanized = zu
fully human = u
two antibody-drug conjugates to know
-trastuzumab emtansine
-trastuzumab deruxtecan
trastuzumab emtansine: what is emtansine’s role?
inhibits microtubule assembly
SE of emtansine (2 of them)
thrombocytopenia, hepatotoxicity
which BiTE binds to CD3 and brings activated T-cell into proximity of CD19?
a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab
a. blinatumomab
which BiTE targets CD3 and CD20?
a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab
b. mosunetuzumab
which BiTE targets CD3 on T cells and B-cell maturation antigen (BCMA) on multiple myeloma cells?
a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab
c. teclistamab
which BiTE targets CD3 on T cells and human G-protein coupled receptor family C group 5 member D (GPRC5D) on multiple myeloma cells?
a. blinatumomab
b. mosunetuzumab
c. teclistamab
d. taquetamab
d. taquetamab
which class of drugs causes cytokine release syndrome?
BiTE’s
PD-1 is expressed on which of the following? SELECT ALL THAT APPLY
a. T-cells
b. macrophages
c. tumor cells
a. T-cells
PD-L1 is expressed on which of the following? SELECT ALL THAT APPLY
a. T-cells
b. macrophages
c. tumor cells
b. macrophages
c. tumor cells
goal of Sipulcel-T (Provenge)
to stimulate a pt’s own immune system to attack the cancer
which agent is a PAP-GM-CSF?
Sipulcel-T (Provenge)
target for CAR-T therapies from class
CD19
Sipulcel-T can cause flu-like symptoms and a possible inc risk of ______
stroke
The antibody Fakeumab has just entered the market. What type of the antibody was it?
a. Fully human
b. Humanized
c. Fully mouse
d. Chimeric
a. Fully human
Which antibody is effective against metastatic melanoma and targets CTLA-4?
a. Ipilimumab
b. Trastuzumab
c. Daratumumab
d. Blinatumomab
a. Ipilimumab
Which of the following proteins is used as a cancer biomarker test to determine eligibility for treatment of NSCLC with pemrolizumab?
a. CD19
b. CTLA4
c. PDL1
d. PD1
c. PDL1
Which of the following antigens is a common target for CAR-T therapy in B cell malignancy?
A) CD4
B) CD19
C) CD28
D) CTLA4
B) CD19
What is the primary mechanism of action of bispecific T cell engagers in cancer immunotherapy?
A) They inhibit the PD1/PDL1 interaction
B) They bring T cells and cancer cells in close proximity to facilitate T cell mediated cytotoxicity
C) They stimulate the innate immune system to recognize tumor cells.
D) They increase neoantigens.
B) They bring T cells and cancer cells in close proximity to facilitate T cell mediated cytotoxicity
